Drug Profile
Research programme: dementia therapeutics - Muscagen
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Cardiff University; University of Manchester
- Developer Muscagen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dementia
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Dementia in United Kingdom (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Dementia in United Kingdom